Combination of auraptene and arsenic trioxide induces apoptosis and cellular accumulation in the subG1 phase in adult T-cell leukemia cells

Document Type : Original Article


1 Immunology Research Center, Inflammation and inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Hematology and Blood Bank, Tabas School of Nursing, Birjand University of Medical Sciences, Birjand, Iran

3 Department of Pharmacognosy and Biotechnology, Biotechnology Research Center, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

4 Blood Borne Infections Research Center, Academic Center for Education, Culture, and Research (ACECR), Razavi Khorasan, Mashhad, Iran

5 Novel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran


Objective(s): Despite advances in the treatment of adult T-cell leukemia/lymphoma (ATLL), the survival rate of this malignancy remains significantly low. Auraptene (AUR) is a natural coumarin with broad-spectrum anticancer activities. To introduce a more effective therapeutic strategy for ATLL, we investigated the combinatorial effects of AUR and arsenic trioxide (ATO) on MT-2 cells.
Materials and Methods: The cells were treated with different concentrations of AUR for 24, 48, and 72 hr, and viability was measured by alamarBlue assay. Then, the combination of AUR (20 μg/ml) and ATO (3 μg/ml) was administrated and the cell cycle was analyzed by PI staining followed by flow cytometry analysis. In addition, the expression of NF-κB (REL-A), CD44, c-MYC, and BMI-1 was evaluated via qPCR.
Results: Assessment of cell viability revealed increased toxicity of AUR and ATO when used in combination. Our findings were confirmed by accumulation of cells in the sub G1 phase of the cell cycle and significant down-regulation of NF-κB (REL-A), CD44, c-MYC, and BMI-1.
Conclusion: Obtained findings suggest that combinatorial use of AUR and ATO could be considered for designing novel chemotherapy regimens for ATLL.


1. Hermine O, Ramos JC, Tobinai K. A review of new findings in adult T-cell leukemia-lymphoma: A focus on current and emerging treatment strategies. Adv Ther 2018; 35:135-152.
2. Cook LB, Elemans M, Rowan AG, Asquith B. HTLV-1: Persistence and pathogenesis. Virology 2013; 435:131-140.
3. Qayyum S, Choi JK. Adult T-cell leukemia/lymphoma. Arch Pathol Lab Med 2014; 138:282-286.
4. Nosaka K, Matsuoka M. Adult T-cell leukemia-lymphoma as a viral disease: Subtypes based on viral aspects. Cancer Sci 2021;112:1688-1694.
5. Cherian MA, Baydoun HH, Al-Saleem J, Shkriabai N, Kvaratskhelia M, Green P, et al. Akt pathway activation by human t-cell leukemia virus type 1 Tax oncoprotein. J Biol Chem 2015; 290:26270-26281.
6. Matsuoka M, Yasunaga J. Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. Curr Opin Virol 2013; 3:684-691.
7. Giam CZ, Semmes OJ. HTLV-1 infection and adult T-cell leukemia/lymphoma-A tale of two proteins: Tax and HBZ. Viruses 2016;8:161. 
8. Nicot C. HTLV-I tax-mediated inactivation of cell cycle checkpoints and DNA repair pathways contribute to cellular transformation: “a random mutagenesis model”. J Cancer Sci 2015; 2.
9. Bazarbachi A, Abou Merhi R, Gessain A, Talhouk R, El-Khoury H, Nasr R, et al. Human T-cell lymphotropic virus type I-infected cells extravasate through the endothelial barrier by a local angiogenesis-like mechanism. Cancer Res 2004; 64:2039-2046.
10. Harakeh S, Azar R, Azhar E, Damanhouri GA, Assidi M, Abu-Elmagd M, et al. Pecific nutrient combination effects on tax, NF- kappaB and MMP-9 in human T-cell lymphotropic virus -1 positive malignant T-lymphocytes. BMC Cancer 2015; 15 Suppl 1:S2.
11. Harhaj EW, Giam CZ. NF-kappaB signaling mechanisms in HTLV-1-induced adult T-cell leukemia/lymphoma. FEBS J 2018; 285:3324-3336.
12. Basakran NS. CD44 as a potential diagnostic tumor marker. Saudi Med J 2015; 36:273-279.
13. Miyatake Y, Sheehy N, Ikeshita S, Hall WW, Kasahara M. Anchorage-dependent multicellular aggregate formation induces CD44 high cancer stem cell-like ATL cells in an NF-kappaB- and vimentin-dependent manner. Cancer Lett 2015; 357:355-363.
14. Wasylishen AR, Penn LZ. Myc: the beauty and the beast. Genes Cancer 2010; 1:532-541.
15. Dang CV. MYC on the path to cancer. Cell 2012; 149:22-35.
16. Zhao W, Li Y, Zhang X. Stemness-related markers in cancer. Cancer Transl Med 2017; 3:87-95.
17. Yang X, Cai H, Liang Y, Chen L, Wang X, Si R, et al. Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells. Oncol Rep 2015; 33:1723-1730.
18. Mesnard JM, Barbeau B, Cesaire R, Peloponese JM. Roles of HTLV-1 basic zip factor (HBZ) in viral chronicity and leukemic transformation. Potential new therapeutic approaches to prevent and treat HTLV-1-related diseases. Viruses 2015; 7:6490-6505.
19. Bazarbachi A, Suarez F, Fields P, Hermine O. How I treat adult T-cell leukemia/lymphoma. Blood 2011; 118:1736-1745.
20. Lengfelder E, Hofmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2012; 26:433-442.
21. Wang QQ, Jiang Y, Naranmandura H. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases. Metallomics 2020; 12:326-336.
22. Derosa G, Maffioli P, Sahebkar A. Auraptene and its role in chronic diseases. Adv Exp Med Biol 2016; 929:399-407.
23. Tayarani-Najaran Z, Tayarani-Najaran N, Eghbali S. A review of auraptene as an anticancer agent. Frontiers in Pharmacology 2021; 12:698352. 
24. Mousavi SH, Davari AS, Iranshahi M, Sabouri-Rad S, Tayarani Najaran Z. Comparative analysis of the cytotoxic effect of 7-prenyloxycoumarin compounds and herniarin on MCF-7 cell line. Avicenna J Phytomed 2015; 5:520-530.
25. Moussavi M, Haddad F, Rassouli FB, Iranshahi M, Soleymanifard S. Synergy between auraptene, ionizing radiation, and anticancer drugs in colon adenocarcinoma cells. Phytother Res 2017; 31:1369-1375.
26. Movaffagh J, Salari H, Merajifar E, Gholamhosseinian H, Shahroodi A, Iranshahi M, et al. 7-Geranyloxycoumarin enhanced radiotherapy effects on human gastric adenocarcinoma cells.  J Can Res Ther 2021. 
27. Salari H, Afkhami-Poostchi A, Soleymanifard S, Nakhaei-Rad S, Merajifar E, Iranshahi M, et al. Coadministration of auraptene and radiotherapy; a novel modality against colon carcinoma cells in vitro and in vivo. Int J Radiat Biol 2020; 96:1051-1059.
28. Motlagh FM, Gholami O. Comparison of umbelliprenin and auraptene in cytotoxic effects and myeloid cell leukemia type-1 (Mcl-1) gene expression. Indian J Pharm Sci 2017; 78:827-833.
29. Epifano F, Genovese S, Miller R, Majumdar AP. Auraptene and its effects on the re-emergence of colon cancer stem cells. Phytother Res 2013; 27:784-786.
30. Moon JY, Kim H, Cho SK. Auraptene, a major compound of supercritical fluid extract of phalsak (Citrus Hassaku Hort ex Tanaka), induces apoptosis through the suppression of mTOR pathways in human gastric cancer SNU-1 cells. Evid Based Complement Alternat Med 2015; 2015:402385.
31. Saboor-Maleki S, Rassouli FB, Matin MM, Iranshahi M. Auraptene attenuates malignant properties of esophageal stem-like cancer cells. Technol Cancer Res Treat 2017; 16:519-527.
32. Nabekura T, Yamaki T, Kitagawa S. Effects of chemopreventive citrus phytochemicals on human P-glycoprotein and multidrug resistance protein 1. Eur J Pharmacol 2008; 600:45-49.
33. Niu X, Huang Z, Zhang L, Ren X, Wang J. Auraptene has the inhibitory property on murine T lymphocyte activation. Eur J Pharmacol 2015; 750:8-13.
34. Lee JC, Shin EA, Kim B, Kim BI, Chitsazian-Yazdi M, Iranshahi M, et al. Auraptene induces apoptosis via myeloid cell leukemia 1-mediated activation of caspases in PC3 and DU145 prostate cancer cells. Phytother Res 2017; 31:891-898.
35. Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol 2012; 32:3121-3131.
36. Fochi S, Mutascio S, Bertazzoni U, Zipeto D, Romanelli MG. HTLV deregulation of the NF-kappaB pathway: An update on Tax and antisense proteins role. Front Microbiol 2018; 9:285.
37. Hewamana S, Lin TT, Rowntree C, Karunanithi K, Pratt G, Hills R, et al. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 2009; 27:763-769.
38. Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007; 97:523-530.
39. Tanaka T, de Azevedo MB, Duran N, Alderete JB, Epifano F, Genovese S, et al. Colorectal cancer chemoprevention by 2 beta-cyclodextrin inclusion compounds of auraptene and 4’-geranyloxyferulic acid. Int J Cancer 2010; 126:830-840.
40. Tansey WP. Mammalian MYC proteins and cancer. New J Sci 2014; 2014.
41. Zheng K, Cubero FJ, Nevzorova YA. c-MYC-Making Liver Sick: Role of c-MYC in hepatic cell function, homeostasis and disease. genes (Basel) 2017; 8:123.
42. Koh CM, Sabo A, Guccione E. Targeting MYC in cancer therapy: RNA processing offers new opportunities. Bioessays 2016; 38:266-275.
43. Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 2018; 11:64.
44. Hoofd C, Wang X, Lam S, Jenkins C, Wood B, Giambra V, et al. CD44 promotes chemoresistance in T-ALL by increased drug efflux. Exp Hematol 2016; 44:166-171 e117.